The Avalanche Difference
In contrast to the current standard of care which is effective for a short period of time, data from preclinical studies shows that our Ocular Biofactory™ continues to express therapeutic protein, reaching a beneficial level within six to eight weeks. In animal models, the therapeutic effect has been shown to last up to 17 months, and data from other studies with AAV in the retina have shown gene expression to last more than five years. In humans, AVA-101 has been studied for up to one year, and we believe it has the potential to last much longer.
